Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Instituto Carlos Slim De La Salud, A.c.

Bayer Aktiengesellschaft

Amael Madec

Philip Lienau

Ulf Bömer

Markus Berger

Anne Mengel

Detlev Sülzle

Volker Schulze

Todd R Golub

Stefan Kaulfuss

Laura Furst

Ulrike Rauh

Roman Hillig

Ryan Spangler

Rohith Nagari

Steven Corsello

Christian Lechner

Adelaide Clara Faria Alvares De Lemos

Alisha Caliman

Rajesha Rupaimoole

Sven Christian

Kartarzyna Handing

Krzysztof Brzezinka

Jérémie Xavier G Mortier

David Mckinney

Douglas Orsi

Mrinal Shekhar

Katarzyna Handing

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.

Aryl hydrocarbon receptor (AHR) activator compounds as cancer therapeutics

Growing community of inventors

Cambridge, MA, United States of America

Amael Madec